Integer Holdings Corporation
General ticker "ITGR" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $4.0B (TTM average)
Integer Holdings Corporation does not follow the US Stock Market performance with the rate: -19.9%.
Estimated limits based on current volatility of 1.3%: low 84.04$, high 86.09$
Factors to consider:
- Total employees count: 11000 as of 2024
- US accounted for 54.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Customer dependency, Supply chain disruptions, Cybersecurity threats, Integration challenges, Operational and conduct risks
- Current price 25.5% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [112.77$, 160.31$]
- 2025-12-31 to 2026-12-31 estimated range: [115.11$, 164.84$]
Financial Metrics affecting the ITGR estimates:
- Negative: with PPE of 25.2 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 12.13
- Positive: Interest expense per share per price, % of 1.25 <= 3.31
- Positive: -4.41 < Investing cash flow per share per price, % of -4.35
- Negative: negative Industry operating cash flow (median)
- Positive: 1.77 < Return on assets ratio (scaled to [-100,100]) of 3.78
- Negative: Industry earnings per price (median), % of -3.88 <= 0
- Negative: 42.53 < Shareholder equity ratio, % of 52.61 <= 64.17
Short-term ITGR quotes
Long-term ITGR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,331.28MM | $1,555.66MM | $1,716.60MM |
| Operating Expenses | $1,218.60MM | $1,392.33MM | $1,508.36MM |
| Operating Income | $112.68MM | $163.32MM | $208.24MM |
| Non-Operating Income | $-44.00MM | $-57.94MM | $-60.67MM |
| Interest Expense | $37.27MM | $51.27MM | $56.37MM |
| R&D Expense | $59.76MM | $61.97MM | $53.42MM |
| Income(Loss) | $68.68MM | $105.38MM | $147.56MM |
| Taxes | $8.93MM | $16.24MM | $26.51MM |
| Other Income(Loss) | $6.63MM | $1.51MM | $-1.16MM |
| Profit(Loss)* | $73.01MM | $92.16MM | $121.05MM |
| Stockholders Equity | $1,417.46MM | $1,519.04MM | $1,619.21MM |
| Inventory | $208.77MM | $229.10MM | $247.13MM |
| Assets | $2,794.39MM | $2,942.65MM | $3,077.97MM |
| Operating Cash Flow | $116.38MM | $180.21MM | $205.21MM |
| Capital expenditure | $74.73MM | $119.94MM | $105.61MM |
| Investing Cash Flow | $-200.42MM | $-163.37MM | $-195.41MM |
| Financing Cash Flow | $92.48MM | $-18.01MM | $13.32MM |
| Earnings Per Share** | $2.20 | $2.77 | $3.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.